In the BioHarmony Drug Report Database
Loncastuximab tesirine
Zynlonta (loncastuximab tesirine) is an antibody pharmaceutical. Loncastuximab tesirine was first approved as Zynlonta on 2021-04-23. It is used to treat large b-cell lymphoma diffuse in the USA. It is known to target B-lymphocyte antigen CD19.
Trade Name
|
Zynlonta |
|---|---|
Common Name
|
loncastuximab tesirine |
ChEMBL ID
|
CHEMBL4297778 |
Indication
|
large b-cell lymphoma diffuse |
Drug Class
|
Monoclonal antibodies: chimeric, tumors as target |
Image (chem structure or protein)
